PDF Version

PDF 版本

RNS Number : 9985H

RNS编号：9985H

PureTech Health PLC

纯科技健康有限公司

09 May 2025

2025年5月9日

9 May 2025

2025年5月9日

PureTech Health plc

纯科技健康有限公司

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

PureTech宣布发布新研究，重点介绍特发性肺纤维化（IPF）患者未被讲述的经历。

Research conducted in collaboration with

与...合作进行的研究

IPF experts and t

IPF专家和t

he

他

Pulmonary Fibrosis Foundation

肺纤维化基金会

reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF

揭示了IPF患者在诊断、治疗和生活质量方面的关键差距

Findings highlight the profound physical, emotional, and psychosocial burden of IPF and underscore urgent need for enhanced education, streamlined diagnosis, patient-focused treatment plans, and more effective therapies

研究结果强调了IPF所带来的深远的身体、情感和社会心理负担，并突显了对加强教育、简化诊断、以患者为中心的治疗计划以及更有效疗法的迫切需求。

PureTech Health plc

PureTech Health plc

(Nasdaq: PRTC, LSE: PRTC) ('

（纳斯达克：PRTC，伦敦证券交易所：PRTC）（'

PureTech

纯技术

' or the 'Company'),

‘或’公司‘），

a

a

clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the publication of new research in

临床阶段的生物治疗公司，致力于改变患有严重疾病的患者的生活，今天宣布了新研究的发表在

BMC Pulmonary Medicine

BMC肺病学

that provides a comprehensive view into the lived experiences of people with idiopathic pulmonary fibrosis (IPF)

提供了对特发性肺纤维化（IPF）患者生活经历的全面了解

.

。

Conducted in collaboration with

与...合作进行

Tejaswini Kulkarni

特贾斯维尼·库尔卡尼

, MD, MPH, from the

，医学博士，公共卫生硕士，来自

University of Alabama at Birmingham

阿拉巴马大学伯明翰分校

,

，

Lisa Lancaster

丽莎·兰开斯特

, MD, from

，医学博士，来自

Vanderbilt University Medical Center

范德比尔特大学医学中心

, and

，以及

Jessica Shore, RN

杰西卡·肖尔，注册护士

, PhD, from the

，博士，来自

Pulmonary Fibrosis Foundation

肺纤维化基金会

(PFF), the study identifies critical barriers to treatment, opportunities for improved community engagement, and the need for patient-centered approaches in the development of new therapeutics

(PFF)，该研究确定了治疗的关键障碍、改进社区参与的机会，以及在新疗法开发中对以患者为中心的方法的需求。

.

。

Initial findings from this research were presented at the 2023 Pulmonary Fibrosis Foundation Summit, the

这项研究的初步结果在 2023 年肺纤维化基金会峰会上公布，

American Thoracic Society

美国胸科学会

2024

2024

International Conference

国际会议

, and the CHEST 2024 Annual Meeting.

，以及2024年胸科年会。

'It's remarkable that despite the availability of approved therapies, antifibrotic uptake remains persistently low. This lack of engagement reflects not just clinical barriers but fundamental gaps in understanding the experiences of people living with IPF, and we wanted to highlight their voices in this study,' said .

“尽管有已获批的疗法可用，但抗纤维化的应用率仍然持续偏低，这令人瞩目。这种缺乏参与的情况不仅反映了临床障碍，还反映了对特发性肺纤维化患者生活体验的基本理解存在差距，我们希望在这项研究中突出他们的心声，”研究人员表示。

Camilla Graham

卡米拉·格雷厄姆

, MD, MPH, Senior Vice President of Medical Affairs at

医学博士，公共卫生硕士，医疗事务高级副总裁 at

PureTech

纯技术

and lead author of the study. 'By integrating the perspectives of people with IPF into every stage of diagnosis, disease management, education, and clinical development, we have a real opportunity to shift the paradigm for IPF care to one that is more empathetic, effective, and aligned with the realities of living with this serious disease.

这项研究的主要作者表示：“通过将特发性肺纤维化（IPF）患者的观点融入到诊断、疾病管理、教育和临床开发的每个阶段，我们有机会真正转变IPF护理的模式，使其更具同理心、更有效，并与这种严重疾病的现实情况相契合。

This study is just the beginning.

这项研究仅仅是一个开始。

;

；

academic centers, professional societies, advocacy organizations, and pharmaceutical companies need to continue to collaborate on patient-informed innovation that bridges the current gaps in diagnosis, treatment, and quality of life.'

学术中心、专业协会、倡导组织和制药公司需要继续合作，开展以患者为中心的创新，弥补当前在诊断、治疗和生活质量方面的差距。

'As a clinician and researcher deeply involved in the care of individuals with IPF, I often witness the challenges patients face in understanding their diagnosis and treatment options,' said

“作为一名深入参与IPF患者护理的临床医生和研究人员，我经常目睹患者在理解自己的诊断和治疗选择方面面临的挑战，”

Dr. Kulkarni

库尔卡尼博士

. 'This work uniquely captures the real-world experiences of people living with IPF, bringing to light critical gaps in education, awareness, and early intervention that we see play out in everyday clinical practice. By integrating these perspectives into our clinical strategies and research priorities, we have the opportunity to drive more empathetic, effective care that aligns with what truly matters to those living with IPF.'.

“这项工作独特地捕捉了特发性肺纤维化（IPF）患者的真实生活体验，揭示了我们在日常临床实践中看到的教育、意识和早期干预方面的关键差距。通过将这些视角整合到我们的临床策略和研究重点中，我们有机会推动更具同理心和更有效的护理，与IPF患者真正关心的问题保持一致。”

'At the

'在

Pulmonary Fibrosis Foundation

肺纤维化基金会

, our mission is to accelerate the development of new treatments and improve the quality of life for people affected by pulmonary fibrosis. This study provided an opportunity to truly listen to patients, capturing their experiences with diagnosis, antifibrotic therapy, and oxygen use-areas where we know there are gaps in understanding and support,' said .

，我们的使命是加速新疗法的开发，并改善肺纤维化患者的生活质量。这项研究提供了一个真正倾听患者意见的机会，捕捉他们在诊断、抗纤维化治疗和氧气使用方面的体验——这些领域是我们知道在理解和支持方面存在差距的地方，

Dr. Shore

肖尔博士

. 'These findings highlight the critical need for high-quality educational resources, to strengthen advocacy efforts, and to enhance collaboration with healthcare providers to ensure that patient voices remain at the center of care decisions.'

“这些发现突显了对高质量教育资源的关键需求，以加强宣传努力，并增强与医疗保健提供者的协作，确保患者的声音始终处于护理决策的中心。”

Key research highlights include:

主要研究亮点包括：

1.

1.

The need for enhanced disease awareness and education

加强对疾病的认识和教育的必要性

·

·

Diagnosis timelines varied widely, with some participants experiencing

诊断时间线差异很大，一些参与者经历了

years of delays a

多年的延迟

nd extensive evaluations for other conditions before receiving an IPF diagnosis. These findings underscore the need for an increase in awareness campaigns and more efficient diagnostic protocols to ensure earlier identification and intervention.

在获得IPF诊断之前，对其他病症进行了广泛评估。这些发现强调了加强宣传运动和更有效诊断协议的必要性，以确保及早识别和干预。

·

·

While the majority of participants expressed satisfaction with their healthcare provider interactions, most also turned to the internet and support groups for information. This underscores the need for widely accessible, high-quality resources about IPF and its management.

虽然大多数参与者对与医疗保健提供者的互动表示满意，但大多数人也转向互联网和支持小组获取信息。这强调了对广泛可及的、关于IPF及其管理的高质量资源的需求。

·

·

IPF affected many aspects of participants' lives, including their ability to keep up with family, work, travel, and household tasks, while also straining relationships with family and friends. This highlights the need to enhance management strategies that address not only the physical but also the emotional and psychological needs of people living with IPF and their caregivers..

IPF影响了参与者生活的许多方面，包括他们跟上家庭、工作、旅行和家务任务的能力，同时也给与家人和朋友的关系带来了压力。这突显了需要加强管理策略，不仅要满足IPF患者及其护理人员的身体需求，还要关注他们的情感和心理需求。

2.

2.

The perceived impact of antifibrotics and the need for clearer treatment expectations

抗纤维化药物的感知影响及对更明确治疗期望的需求

·

·

Of the participants who had never been treated with an antifibrotic, the most common reason for delay was that they were waiting until their symptoms worsened, highlighting a critical gap in understanding the potential benefits of early intervention.

在从未接受过抗纤维化治疗的参与者中，延迟治疗的最常见原因是他们打算等到症状恶化，这凸显了对早期干预潜在益处认识上的关键差距。

·

·

While the majority of participants on antifibrotics reported that their medication helped slow disease progression, many

虽然大多数使用抗纤维化药物的参与者报告说，他们的药物有助于减缓疾病进展，但许多 người dùng vẫn gặp phải các vấn đề. （注：此处越南语混入，正确翻译应为：）虽然大多数使用抗纤维化药物的参与者报告说，他们的药物有助于减缓疾病进展，但许多用户仍然遇到问题。

still found it difficult to perceive

仍然觉得难以理解

tangible benefits

实际利益

due to the lack of visible improvements

由于缺乏明显的改进

.

。

Additionally, side effects associated with antifibrotic treatments often impacted quality of life, leading some participants to reduce dosing or discontinue therapy - further complicating perceptions of effectiveness. Despite these challenges, most people taking antifibrotics shared that the treatment gave them hope.

此外，与抗纤维化治疗相关的副作用常常影响生活质量，导致一些参与者减少剂量或停止治疗，这进一步复杂了对疗效的感知。尽管存在这些挑战，大多数服用抗纤维化药物的人表示，这种治疗给了他们希望。

These findings emphasize the need for clearer communication about the expected benefits and limitations of antifibrotic therapy, as well as strategies to manage side effects and maintain therapeutic benefit..

这些研究结果强调了需要更清楚地传达关于抗纤维化治疗的预期益处和局限性，以及管理副作用和维持治疗效果的策略。

·

·

The study explored both the adverse effects participants ascribed to their antifibrotic treatment and the broader impact of managing those side effects on daily life. More than half adjusted their dosing to help manage adverse effects. These findings suggest opportunities for more patient-centered education on symptom management and highlight the need for better-tolerated medications to treat IPF..

该研究探讨了参与者归因于其抗纤维化治疗的不良影响，以及管理这些副作用对日常生活产生的更广泛影响。超过一半的参与者调整了剂量以帮助管理不良反应。这些发现表明，有必要进行更多以患者为中心的症状管理教育，并强调了对更好耐受性药物的需求，以治疗特发性肺纤维化（IPF）。

·

·

Clear, empathetic communication between healthcare providers and patients is essential to set realistic expectations, manage consequences of IPF and side effects of antifibrotic treatment, and empower patient engagement with all aspects of their care.

医疗保健提供者与患者之间清晰且富有同理心的沟通，对于设定现实预期、管理IPF的后果及抗纤维化治疗的副作用，以及增强患者参与自身护理各方面的主动性至关重要。

3.

3.

The need for coordinated care to manage multiple comorbidities

管理多种合并症的协调护理需求

·

·

Nearly 90% of study participants reported managing additional health challenges alongside IPF, underscoring the importance of coordinated care among IPF-treating providers and the broader care team.

近90%的受访者表示，除了特发性肺纤维化（IPF）之外，他们还在应对其他健康问题，这凸显了IPF治疗医生与更广泛的医疗团队之间协调治疗的重要性。

·

·

The prevalence of comorbidities suggests that improving communication and strategic care planning across specialties could improve outcomes and overall quality of life for people living with IPF. Integrated care pathways that address both IPF and its comorbidities could significantly reduce the burden on people living with IPF and their caregivers..

合并症的普遍性表明，改善跨专科的沟通和战略性护理规划可以改善特发性肺纤维化（IPF）患者的结果和整体生活质量。解决IPF及其合并症的综合护理路径可以显著减轻IPF患者及其护理者的负担。

4.

4.

The need for holistic support in managing the benefits and burdens of supplemental oxygen

管理补充氧气的益处与负担所需的全面支持

·

·

While participants widely recognized the symptom relief provided by supplemental oxygen therapy, many described the associated logistical challenges, daily disruptions, financial burdens, and emotional toll. These insights underscore the need for treatment planning that accounts for both the benefits and challenges of oxygen therapy, while exploring innovations in delivery and holistic support to enhance quality of life..

尽管参与者普遍认可补充氧气疗法带来的症状缓解，但许多人描述了与此相关的物流挑战、日常生活干扰、经济负担和情感压力。这些见解强调了在治疗规划中需要同时考虑氧气疗法的益处与挑战，并探索输送方式的创新及整体支持，以提高生活质量。

The research, which included 106 people living with IPF across

该研究包括了 106 名特发性肺纤维化（IPF）患者

the United States

美国

, utilized both qualitative interviews and online surveys to capture their experiences. Sponsored by

，利用定性访谈和在线调查相结合的方式，捕捉他们的体验。 赞助方为

PureTech

纯技术

, the study underscores the Company's commitment to amplifying patient voices in the development of breakthrough treatments. By understanding the lived experiences and unmet needs of people with IPF,

，该研究强调了公司致力于在突破性治疗的开发中放大患者的声音。通过了解特发性肺纤维化（IPF）患者的亲身经历和未满足的需求，

PureTech

纯科技

aims to drive meaningful advances in care, education, and therapeutic development that are deeply reflective of patient realities. The paper, titled '

旨在推动在护理、教育和治疗发展方面取得有意义的进展，这些进展深刻反映了患者的实际情况。这篇论文题为‘

Perspectives of People Living with Idiopathic Pulmonary Fibrosis: A Qualitative and Quantitative Study

特发性肺纤维化患者的生活视角：一项定性和定量研究

,' is now available on the journal's website.

，现在可以在期刊的网站上获取。

Acknowledgments and Appreciation

致谢与赞赏

PureTech

纯技术

would like to extend its sincere gratitude to all the participants who generously shared their time and experiences to make this research possible.

衷心感谢所有参与者慷慨分享他们的时间和经验，使本研究得以实现。

PureTech

纯技术

is also grateful to the

也非常感谢

Pulmonary Fibrosis Foundation

肺纤维化基金会

and Breathe Support Network, whose support was instrumental in developing a comprehensive study that reached a diverse group of participants to provide these critical insights.

和呼吸支持网络，他们的支持对于开展这项全面的研究至关重要，这项研究接触到了多样化的参与者群体，提供了这些关键的见解。

PureTech

纯科技

is proud to amplify the voices of those living with IPF and remains committed to fostering patient-driven innovation and care that is reflective of real-world needs.

很自豪能够放大IPF患者的声音，并继续致力于推动反映现实需求的患者驱动创新和护理。

About Idiopathic Pulmonary Fibrosis (IPF)

关于特发性肺纤维化 (IPF)

Idiopathic Pulmonary Fibrosis (IPF) is a rare, progressive and fatal lung disease characterized by irreversible scarring of lung tissue. Median survival following diagnosis is estimated to be two to five years.

特发性肺纤维化 (IPF) 是一种罕见的、进行性的且致命的肺部疾病，其特征是肺组织不可逆的瘢痕化。诊断后的中位生存期估计为两到五年。

[1]

[1]

IPF affects more than 230,000 people across

IPF影响着超过23万人

the United States

美国

and EU5 (

和 EU5 (

France

法国

,

，

Germany

德国

,

，

Italy

意大利

,

，

Spain

西班牙

, and the

，以及

United Kingdom

英国

)

)

[2]

[2]

.

。

Although two therapies are approved to treat IPF, their use remains limited, and nearly three out of four people with IPF in

虽然有两种疗法被批准用于治疗IPF，但它们的使用仍然有限，近四分之三的IPF患者

the United States

美国

have never received either treatment.

从未接受过任何一种治疗。

[3]

[3]

There remains a significant need for therapies that can more effectively slow or stabilize disease progression, improve long-term outcomes, and maintain quality of life for people living with IPF.

仍然迫切需要能够更有效地减缓或稳定疾病进展、改善长期预后并维持特发性肺纤维化（IPF）患者生活质量的治疗方法。

About PureTech Health

关于PureTech Health

PureTech

纯技术

is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. .

是一家处于临床阶段的生物治疗公司，致力于为毁灭性疾病患者开发新类别的药物以改变他们的生活。公司通过其经验丰富的研发团队以及广泛的科学家、临床医生和行业领袖网络，建立了广泛而深入的产品组合，这些产品组合正在通过内部及其创始实体共同推进。

PureTech's

纯技术的

R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the

研发引擎已促成29种治疗药物和候选治疗药物的开发，其中三种已获得批准。

U.S. Food and Drug Administration

美国食品药品监督管理局

. A number of these programs are being advanced by

其中许多项目正在由

PureTech

纯科技

or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the

或其成立的实体在各种适应症和临床开发阶段，包括注册支持研究。所有导致这一治疗候选药物组合的底层项目和平台最初都是由该公司识别或发现，然后推进的。

PureTech

纯技术

team through key validation points.

通过关键验证点的团队。

For more information, visit

欲了解更多信息，请访问

www.puretechhealth.com

www.puretechhealth.com

or connect with us on X (formerly Twitter) @puretechh.

或通过X（原Twitter）@puretechh与我们联系。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的谨慎声明

This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our idiopathic pulmonary fibrosis program and development plans, our future prospects, developments and strategies.

本新闻稿包含符合1995年《私人证券诉讼改革法案》定义的前瞻性陈述。本新闻稿中所有不涉及历史事实的陈述均应被视为前瞻性陈述，包括但不限于与我们的特发性肺纤维化项目及开发计划、未来前景、发展和战略相关的陈述。

The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the .

前瞻性声明基于当前预期，但可能受到已知和未知风险、不确定性以及其他重要因素的影响，这些因素可能导致实际结果、表现或成就与当前预期存在重大差异。这些风险、不确定性及其他重要因素包括但不限于我们在截至2024年12月31日的年度20-F表格年报中“风险因素”标题下描述的内容，该报告已提交给。

SEC

证券交易委员会

and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release.

并包含在我们的其他监管文件中。这些前瞻性陈述是基于公司当前和未来业务战略的假设，以及公司未来运营所处的环境。每个前瞻性陈述仅代表本新闻稿发布之日的情况。

Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. .

除非法律和监管要求另有规定，我们不承担更新或修改这些前瞻性陈述的义务，不论这是由于新信息、未来事件或其他原因。

Contact:

联系：

PureTech

纯科技

Public Relations

公共关系

publicrelations@puretechhealth.com

公共关系@普尔科技健康.com

Investor Relations

投资者关系

IR@puretechhealth.com

IR@puretechhealth.com

UK

英国

/EU Media

欧盟媒体

Ben Atwell

本·阿特韦尔

,

，

Rob Winder

罗布·温德

+44 (0) 20 3727 1000

+44 (0) 20 3727 1000

puretech@fticonsulting.com

纯技术@fticonsulting.com

US Media

美国媒体

Justin Chen

陈贾斯汀

jchen@tenbridgecommunications.com

jchen@tenbridgecommunications.com

[1]

[1]

Fisher, M., Nathan, S. D., Hill, C., Marshall, J.,

费舍尔，M.，内森，S. D.，希尔，C.，马歇尔，J.，

Dejonckheere

德容克尔

, F., Thuresson, P., & Maher, T. M. (2017). Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis.

，F., Thuresson, P., & Maher, T. M. (2017). 预测吡非尼酮在特发性肺纤维化中的预期寿命。

Journal of Managed Care & Specialty Pharmacy

管理式医疗与专科药房杂志

, 23(3-b Suppl), S17-S24.

，23（3-b增刊），S17-S24。

https://doi.org/10.18553/jmcp.2017.23.3-b.s17

https://doi.org/10.18553/jmcp.2017.23.3-b.s17

[2]

[2]

GlobalData Epidemiology and Market Size Search, EU5=

全球数据流行病学与市场规模搜索，欧盟五国=

United Kingdom

英国

,

，

France

法国

,

，

Germany

德国

,

，

Italy

意大利

and

和

Spain

西班牙

[3]

[3]

Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH. Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2021 Jul;18(7):1121-1128

德普西 TM，佩恩 S，桑加拉林厄姆 L，姚 X，沙赫 ND，林佩尔 AH。特发性肺纤维化患者抗纤维化药物吡非尼酮和尼达尼布的采用情况。《美国胸科学会年鉴》。2021年7月；18(7):1121-1128。

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the

此信息由RNS的非监管新闻稿分发服务Reach提供，属于

London Stock Exchange

伦敦证券交易所

. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact

。使用和分发此信息的相关条款和条件可能适用。欲了解更多信息，请联系

rns@lseg.com

rns@lseg.com

or visit

或访问

www.rns.com

www.rns.com

.

。

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the .

RNS可能会使用您的IP地址来确认您是否遵守条款和条件，分析您如何与本通讯中包含的信息互动，并在我们的商业服务范围内以匿名方式与他人分享此类分析。有关RNS如何使用信息的更多详情以及。

London Stock Exchange

伦敦证券交易所

use the personal data you provide us, please see our

使用您提供给我们的个人数据，请参阅我们的

Privacy Policy

隐私政策

.

。

END

结束

NRAEAESNEDXSEEA

NRAEAESNEDXSEEA